

Amy M. Vandenberg, PharmD, BCPP

SC Pharmacy License # 9958
MI Pharmacist License #5302300363

amberg@med.umich.edu

Education

University of Michigan - College of Pharmacy, Ann Arbor, Michigan

- Doctor of Pharmacy, June 1999

University of Michigan – College of Literature, Science and the Arts, Ann Arbor, Michigan

- BS Biopsychology, December 1994

Professional Experience

2020 to present	Clinical Associate Professor University of Michigan College of Pharmacy
2016 to 2020	Adjunct Clinical Associate Professor University of Michigan College of Pharmacy
2016 to present	Clinical Pharmacy Specialist Psychiatry & Neurology Michigan Medicine Department of Pharmacy Services Residency Program Director PGY2 Psychiatric Pharmacy Michigan Medicine
2002 –2016	Pharmacy Coordinator/Clinical Specialist Pharmacist in Charge 2005-2011 and 2015-present Medical University of South Carolina (MUSC) Department of Pharmacy Services/Institute of Psychiatry (IOP) Adjunct Clinical Assistant Professor MUSC College of Pharmacy Department of Clinical Pharmacy and Outcomes Sciences MUSC College of Medicine (2008-present) Department of Psychiatry and Behavioral Sciences Residency Program Director PGY1 with emphasis in Psychiatry PGY2 Psychiatric Pharmacy MUSC Medical Center & College of Pharmacy
2001 –2002	Assistant Professor, Pharmacy Practice Nova Southeastern University (NSU) College of Pharmacy Clinical Pharmacist – South Florida State Hospital Fort Lauderdale, Florida
2000 - 2001	Psychiatric Pharmacy Practice Resident - MUSC
1999 - 2000	Pharmacy Practice Resident - MUSC

05/22/23

Committee Involvement (Hospital, Residency)

2021-2023	Michigan Medicine Alcohol Withdrawal Guideline Interdisciplinary Workgroup
2019-2022	Michigan Medicine Ambulatory Guidelines for Clinical Care: Attention-Deficit Hyperactivity Disorder Guideline
2018-2021	Michigan Medicine 9C Steering Committee/Improving the Patient Experience Committee
2017-present	Michigan Medicine Medication Reconciliation Oversight Committee
2016-present	Michigan Medicine Pharmacy & Therapeutics Committee ad hoc guest for all neurologic and psychiatric medication related discussions
2016-present	Michigan Medicine Interdisciplinary Restraint Reduction Committee
2016-2018	Michigan Medicine Inpatient Psychiatry Leadership Team
2016-present	Michigan Medicine Residency Advisory Committee
2014-2016	MUSC IOP Epic Local Governance Team
2008- 2016	MUSC Psychiatry Residency Curriculum Committee
2008-2016	MUSC IOP Clinical Executive Committee
2006-2010	MUSC Medication Reconciliation Taskforce
2006-2009	MUSC IOP Engagement Model Roll-out Committee (ad hoc)
2005-2016	MUSC IOP Executive Quality Council/Executive Council for Clinical Operations
2005-2008	MUSC IOP Practice Council
2005-2008	MUSC IOP Research and Outcomes Committee
2005-2016	MUSC Safety Committee (ad hoc)
2004-2012	MUSC IOP General Adult Unit Leadership Planning Committee
2003-2008	MUSC Falls Committee/Safety Committee
2003-2016	MUSC Informatics and Formulary Subcommittee
2002-2016	MUSC Medication Safety Improvement Group – IOP representative
2002-2016	MUSC IOP Hospitalist Team
2002-2016	MUSC Pharmacy & Therapeutics IOP representative
2002-2016	MUSC Pharmacy Residency Committee

Didactic Teaching

2021- present	P621 Pharmacotherapeutics II (UM Nurse Practitioner & Clinical Nurse Specialist Program) - Pharmacology of Antiseizure Agents and Pharmacotherapy of Seizures - Pharmacology and Pharmacotherapy of Psychiatric Disorders: Sedative-hypnotic agents, Antidepressants and Anxiolytics
	P612 Therapeutic Problem Solving II (UM College of Pharmacy) - Headache, Seizures, Status Epilepticus, Dementia, Parkinson Disease
2019-present	UM School of Medicine M4 Psychiatry Residency Prep Course (3 hrs)
2018-present	PGY4 Psychiatry Resident Psychopharmacology Seminar (6-12 hours per year)
2018- present	PGY2 Psychiatry Resident Monthly Lunch and Learn (1 hour/month)
2017- 2022	Guest lecturer- UM School of Social Work – Integrated Health Social Work Class Winter Term (1-2 hours/year)
2016 - 2020	M2 Psychiatry Sequence – Case Discussion Leader
2004 – 2016	MUSC Psychiatry Residency: Coordinator/Instructor PGY-3 Psychopharmacology Seminar (<i>Weekly 1 hour seminar; 12-18 residents/yr</i>)
2008 – 2016	MUSC Psychiatry Fellowships: Psychopharmacology lectures for geriatric and child/adolescent psychiatry fellows (<i>5-8 lectures to 6-12 fellows annually</i>)
2003 - 2008	MUSC COP Pharmacy Disease State Management II: Headache
2003- 2008	MUSC COP Geriatrics Elective – Use of psychotropics in elderly

Didactic Teaching Recognition

MUSC PGY3 Psychiatry Resident Didactic Teacher of the Year 2013, 2015, 2016

Clinical Teaching/Student and Resident Supervision

2019-present	Michigan Medicine Psychiatry Residency Program PGY4 Psychopharmacology Longitudinal Rotation preceptor (3 residents)
--------------	--

2018-present	Michigan Medicine Residency Program Chosen Mentor (5 residents)
2017-present	Michigan Medicine PGY2 Psychiatry Residency Program Director (6 residents)
2016-present	Michigan Medicine PGY1 Residency Preceptor: 36 rotations
2016-present	Michigan Medicine PGY2 Residency Preceptor: 71 rotations
2016-present	Michigan Medicine P4 Student Rotation Preceptor: 48 students
2016-present	UM College of Pharmacy PDI Advisor: 7 students
2003-2016	MUSC Pharmacy Residency Program Director: 22 residents (PGY1-7, PGY2-15)
2002-2016	MUSC P4 Student Rotation Preceptor: 93 students
2002-2016	MUSC Pharmacy Residency Program PGY1 Rotation Preceptor: 141 rotations
2002-2016	MUSC Pharmacy Residency Program PGY2 Rotation Preceptor: 140 rotations

Staff Training

March 3, 2022	Residency preceptor training (1 hour) providing constructive feedback
2018 – present	Resident orientation session on professionalism and wellness
2017-present	Nursing staff updates quarterly
2006-2016	Monthly 1 hr psychopharmacology update – all PGY1-PGY5 Psychiatry Residents
2002-2016	Instructor for monthly New Employee Orientation: Psychopharmacology Review for all incoming interdisciplinary staff at the Institute of Psychiatry

Invited CE Presentations

April 18, 2023	Rapid Responses: Management of Psychiatric Emergencies. American Association of Psychiatric Pharmacists Annual Meeting; Atlanta, GA. (ACPE)
November 3, 2022	An update on recently approved long-acting injectable antipsychotics: Knowns and unknowns regarding their use. (BCPP Recertification Review Article)
April 14, 2022	Medications for ADHD: The New and the Reinvented; Michigan Institute for Care Management & Transformation (Nursing and Social Work CE)
October 13, 2020	Wellness, Resilience and Burnout in Pharmacy Residency Training; Michigan Society of Health-System Pharmacists (ACPE)
August 26, 2019	Psychopharmacology Update; Michigan Medicine Psychiatric Emergency Services (CNE)
February 13, 2019	Southeastern Michigan Society of Health-System Pharmacists. Psychotropics: The New, the Old and the Reinvented (ACPE)
December 11, 2018	Medication Management and ECT; Michigan Medicine ECT Nursing Staff (CNE)
October 3, 2018	Pain Management in Psychiatry; Michigan Medicine Psychiatric Emergency Service RN Education Series (CNE)
September 27, 2018	Treatment of BPSD; Dementia, What Now? Interventions for the Patient and Caregiver After the Diagnosis Conference (CME and SW CE)
December 7, 2017	Treatment of Acute Agitation and Anxiety in Inpatient Psychiatry; Psychiatry Nursing Education Day (CNE)
October 26, 2017	Tom D. Rowe 66 th Annual Pharmacy Lectures: Psychiatric Pharmacy Now and Future (ACPE)
March 13, 2016	Treatment of Major Depressive Disorder: Old Dogs, New Tricks; SCSHP Annual Meeting (ACPE)
April 28, 2014	Impact of Drug Shortages on the Provision of ECT; CPNP Annual Meeting (ACPE)
May 2013	Treatment of Major Depressive Disorder: Old Dogs, New Tricks; Family Medicine New Drug Update (CME)
May 29, 2009	“New” Medications on the Horizon; Spoleto Update (CME)
April 2008	ADHD Update; Spoleto Update (CME)
November 4, 2007	ADHD Update; SCSHP Annual Meeting (ACPE)
March 6, 2007	Dealing with Psychiatric Issues in Medically Ill Patients; SCSHP Spring Symposium (ACPE)
January 20, 2005	Prevention of Patient Falls; Med U Way Series (ACPE, CME, CNE)

May 20, 2004	Update on Bipolar Disorders and Treatment; Family Medicine Annual New Drug Update (CME)
January 15, 2004	Appropriate Use of Atypical Antipsychotics in the Hospital Setting; Med U Way Series (ACPE, CME, CNE)
February 4, 2003	Management of Treatment Resistant Schizophrenia; 23 rd National Symposium for Psychiatric Practitioners (ACPE, CNE)
October 10, 2002	Antidepressants in Coronary Artery Disease – A Changing Role; SCSHP Fall Symposium (ACPE)
November 27, 2000	Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder. MUSC Pharmacy Residency Seminar series (ACPE)
March 27, 2000	Analgesic Abuse Headaches. MUSC Pharmacy Residency Seminar series (ACPE)

Research

46. Clinical conundrums of clozapine on consult liaison psychiatry (2022)
45. Relative exposure to psychiatric disease states and medications in pharmacy education. (2021)
44. Home antidepressant prescribing during non-psychiatric hospitalization (2021)
43. Potential interactions between marijuana and psychotropic medications prescribed on inpatient psychiatry unit (2020)
42. Impact of order set changes on utilization of oral lorazepam (2020)
41. Clinical implications of free vs total valproic acid levels (2020)
40. Optimizing use of antidepressant medications in primary care (2019)
39. Patterns of medication use surrounding episodes of violent physical restraints (2019)
38. Effect of medications on electroconvulsive therapy outcomes (2019)
37. Impact of Psychiatric Pharmacist Medication Reconciliation in Psychiatric Emergency Services (2018)
36. VTE Risk Assessment on general adult inpatient psychiatry (2017)
35. Needs assessment for psychiatric pharmacy services (2017)
34. Assessment of Documentation of PRN medication administration (2015)
33. Impact of 30-day Supply of Discharge Medications on 30-day Rehospitalization Rates (2015)
32. Patient vs Staff Impression of Health Care Literacy in Psychiatric Patients (2015)
31. Staff Satisfaction and Competency for CIWA-Ar (2014-2015)
30. Assessment of 30-day Rehospitalization in a Psychiatric Hospital – Contributing Factors (2014)
29. Continuation of Asenapine, Iloperidone, and Lurasidone Versus Haloperidol and Risperidone During Inpatient Psychiatric Hospitalizations: a Retrospective Chart Review (2013)
28. Assessment of Quality and Accuracy of Discharge Medication Reconciliation in Patients with Psychiatric Illness (2012)
27. Collaborating Across the Country: Lessons Learned from a Multi-site, pharmacy resident research project (2012)
26. Evaluation of Consumer and Provider Satisfaction with NAMI Written Medicine Information (2012)
25. A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia. Protocol # R092670PSY3011: Study Drug Manager (2012-2015)
24. Implementation of PharmD Services in a Behavioral Medicine Clinic (2011)
23. A Fifteen Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Incarcerated” Protocol #: R092670SCH3006; Phase 4: Study Drug Manager (2010-2015)
22. Retrospective Review of the Incidence and Course of Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotics (2010)
21. Impact of Pre-treatment with Amobarbital on ECT Outcomes (2010)
20. Retrospective Review of Clinical Outcomes in Geriatric Patients Receiving Nortriptyline Post-ECT (2010)

19. Financial Impact of PharmD Run Long Acting Injectable Antipsychotic Clinic (2009)
18. Rate of 6-Month Follow Up for Long Acting Injectable Antipsychotics Initiated During Hospitalization (2009)
17. Evaluation of Quality of Inpatient Medication Reconciliation (2009)
16. Covance Clinical Study #30-07-247 DeVane (PI) A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Schizophrenia: Study Drug Manager (2009-2015)
15. Covance Clinical Study # 31-108-248 DeVane (PI) A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia: Study Drug Manager (2009-2015)
14. Survey of Physician Perspectives on Automatic Therapeutic Substitutions of Psychiatric Medications (2008)
13. Outpatient Outcomes Following Automatic Therapeutic Substitution of Risperidone to Paliperidone Upon Discharge from Inpatient Psychiatry (2008)
12. Evaluation of Low Dose Quetiapine Use in a Psychiatric Hospital (2007)
11. Assessment of Automatic Therapeutic Substitution Protocol for Paliperidone in a Psychiatric Hospital (2007)
10. Retrospective Review of Concurrent Linezolid and SSRI Therapy (2006)
9. Appropriateness of Therapeutic Drug Monitoring for Mood Stabilizers (2006)
8. Evaluation of Medication Reconciliation Process in a Psychiatric Hospital (2006)
7. Review of Long-Acting Injectable Risperidone in a Psychiatric Hospital (2006)
6. Atypical Antipsychotic Polypharmacy: Documentation of Rationale in Patient Charts (2005)
5. Evaluation of Timeline to Maintenance Antipsychotic Therapy (2005)
4. Assessment of Vital Signs in Children and Adolescents Receiving Medication for the Treatment of ADHD (2005)
3. Monitoring Metabolic Side Effects of Atypical Antipsychotics (2004)
4. Adherence to Prescribing Criteria for Intramuscular Ziprasidone (2003)
2. Prevalence of Atypical Antipsychotic Polypharmacy and Related Outcomes (2003)
1. Assessment of Falls in Non-Geriatric Psychiatry Inpatients (1999)

Other Research Activities

- | | |
|-------------|---|
| 2010 – 2016 | Data Safety Monitoring Board (DSMB): Naltrexone in alcoholics with and without the asp40 OPRM1 gene (PI: Raymond Anton) |
| 2009 – 2016 | DSMB: NAC for cannabis dependence in adolescents (PI: Kevin Gray) |
| 2007 – 2016 | DSMB: Modafanil for cocaine dependence (PI: Raymond Anton) |
| 2007 – 2016 | DSMB: NAC for cocaine dependence (PI: Raymond Anton) |

Publications

44. Marriott M, Schwery A, VandenBerg A. Myasthenia gravis: what does a pharmacist need to know? *Am J Health Syst Pharm.* 2023;80(5):247-257 doi: 10.1093/ajhp/zxac343
43. Winder GS, Andrews SR, Banerjee AG, Hussain F, Ivkovic A, Kuntz K, Omary L, Rasimas JJ, Shenoy A, Thant T, VandenBerg A, Zimbrea P. Cannabinoid and solid organ transplantation: psychiatric perspectives and recommendations. *Transplantation Reviews.* 2022;36(4). <https://doi.org/10.1016/j.trre.2022.100715>
42. VandenBerg, AM. An update on recently approved long-acting injectable antipsychotics: Knowns and unknowns regarding their use. *Mental Health Clinician.* 2022;12(5):270-281. doi: 10.9740/mhc.2022.20.270.
41. Wartman CC, VandenBerg A. Valproate: Not all boxed warnings are created equal. *Ann Pharmacother.* 2022;56(12):1349-1355.
40. O'Connell, M, VandenBerg A. Impact of pharmacist driven medication reconciliation in psychiatric emergency services on length of stay, medication errors, and medication discrepancies. *Drug & Therapy Perspectives.* 2021;37:175-180.
39. Erley J, Goldsborough S, VandenBerg A, Audu A. Loxapine in a patient with clozapine-resistant psychosis. *Ment Health Clin.* 2021;11(4):263-266.

38. Ju V, Walkerly A, VandenBerg A, Shobassy A. Atomoxetine-induced seizures and psychosis due to concomitant use of bupropion: a case report. *J Clin Psychopharmacol*. 2022;42(6):600-602. doi: 10.1097/JCP.0000000000001614
37. Brelje A, Fay B, Marriow S, VandenBerg A. Transaminitis with psychosis: Identifying drug induced liver injury in the setting of acute hepatitis C. *Ment Health Clin*. 2022;12(3):210-213. doi: 10.9740/mhc.2022.06.210.
36. Walkerly A, Leader LD, Cooke E, VandenBerg A. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. *Drug Des Devel Ther*. 2021;15:3017-3026.
35. Irwin M, VandenBerg A. Retracing our steps to understand ketamine in depression: a focused review of hypothesized mechanisms of action. *Ment Health Clin* 2021;11(3):200-210
34. Cusimano J, VandenBerg A. Low-hanging fruit for getting back on your feet: a critical review of diet and exercise interventions for depression. *J Aff Disord Reports*. 2020;12(1). online
33. Chow CL, Kadouh NK, Bostwick JR, VandenBerg AM. Akathisia and newer second-generation antipsychotic drugs: a review of current evidence. *Pharmacotherapy* 2020;40(6):565-574.
32. O'Connell M, VandenBerg A. CYP450 interactions between illicit substances and prescription medications. *Current Psychiatry*. 2020; 19(8):40-42. doi: 10.12788/cp.0288
31. Cusimano J, Martin C, VandenBerg A. Olanzapine-associated edema and decreasing serum lithium concentrations: a case report. *J Clin Psychopharm*. 2020;40(5):499-500.
30. Cusimano J, VandenBerg A. Long-acting injectable antipsychotics and their use in court-ordered treatment: A cross-sectional survey of psychiatric pharmacists' perceptions. *Mental Health Clinician*. 2020;10(1): 18-24.
29. Jones J, VandenBerg A, Malcolm R. Benzodiazepines and Other Sedative Hypnotics. In: *Textbook of Substance Abuse Treatment*. 6th ed. Arlington, VA. American Psychiatric Publishing; pending publication 2019. p. pending.
28. VandenBerg A. Major Depressive Disorder. In: DiPiro J, ed. by. *Pharmacotherapy: A Pathophysiologic Approach*. 11th ed. New York, NY: McGraw-Hill Education; pending publication 2019. p. pending.
27. Leader LD, O'Connell M, VandenBerg A. Brexanolone for postpartum depression: clinical evidence and practical considerations. *Pharmacotherapy*. 2019;39(11):1105-12.
26. Bixby AL, Goldsborough S, Iuppa A, LeBlanc A, Schultz HE, VandenBerg A. Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. *Mental Health Clinician*. 2019;9(5): 331-5.
25. Bixby AL, VandenBerg, A, Bostwick, J. Clinical Management of Bleeding Risk with Antidepressants. *Ann Pharmacother*. 2018; (e pub; doi 10.1177/1060028018794005)
24. McGrane I, VandenBerg A, Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. *Ann Pharmacother*. 2017; 51(11): 1035-6.
23. Bacon O, VandenBerg A, May M. Provider and patient perception of psychiatry patient health literacy. *Pharm Pract*. 2017; 15(2):908-12.
23. Colvard M, Jackson M, Oliveira R, Scholtes K, Burghart S, Gutierrez C, VandenBerg A. Consumer satisfaction with national alliance on mental illness written medicine information. *Ment Health Clin*. 2017;7(2):74-80
22. VandenBerg A, Broadway J. Enteral administration of protein supplement and valproate: a potential pharmacokinetic interaction. *Mental Health Clinician*. 2017; 7(1):10-12.
21. VandenBerg A, Broadway J, Lalich C, Kennedy R, Williams K. Valproate serum concentrations in patients with hypoalbuminemia and medical complications. *Mental Health Clinician*. 2017; 7(1):13-15.
20. Bacon O, Robert S, VandenBerg A. Evaluating nursing satisfaction and utilization of the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar). *Ment Health Clin*. 2016;6(3):114-9.
19. Werremeyer A, VandenBerg A. Headache. In: Murphy J, Lee M, eds. *Pharmacotherapy Self-Assessment Program, 2013-2015 series*. CNS/Pharmacy Practice Module. Kansas City, MO: American College of Clinical Pharmacy, 2015.
18. May M, VandenBerg A. The role of methylphenidate in depression. *Mental Health Clinician*. 2015; 5(6): 271-6.
17. Sigler M, VandenBerg A, Thompson A. Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors in the treatment of painful neuropathy. *Mental Health Clinician*. 2015; 5(6): 289-95.

16. Gwynette MF, Beck B, VandenBerg A, Stocking N. Under arrest: the use of amantadine for treatment-refractory mood lability and aggression in a patient with traumatic brain injury. *J Clin Psychopharmacol.* 2015;35(1):102-4.
15. Freeland KN, Cogdill, BR, Ross Ca, Sullivan CO, Drayton SJ, VandenBerg AM. Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. *AJHP* 2015.72(23):S156-S161.
15. VandenBerg A, Mullis D. Integrating psychiatric PharmD services into an emergency department psychiatry team. *Mental Health Clinician.* 2014;14(6):279-82.
14. VandenBerg A. What's new? Isomers, metabolites and prodrugs, oh my! *Mental Health Clinician.* 2014;4(1):1.
13. VandenBerg A. What is the difference? Within class comparisons of psychotropic agents with new products. *Mental Health Clinician.* 2014;4(1):2-7.
12. Ross C, VandenBerg A, Borckardt J, Short EB. Impact of pretreatment with amobarbital on electroconvulsive therapy outcomes. *J ECT.* 2013;29(1):e10-11.
11. Hebbard AM, Colvard MJ, Book SW, VandenBerg AM. Development of a collaborative drug therapy management protocol for extended-release intramuscular naltrexone. *Ment Health Clin.* 2013; 3(6):292-294.
11. Miller DF, Garcia D, Kreys TJ, Phan SV, VandenBerg A, Garrison KL. Evaluating the Quality of Performance of Medication Reconciliation on Hospital Admission. *Hosp Pharm* 2012;47(7):526-531
10. Freeland KN, Cogdill BR, Ross CA, Sullivan CO, Drayton SJ, VandenBerg AM, Short EB, Garrison KL. Adherence to Evidence-Based Treatment Guidelines for Bipolar Depression in an Inpatient Setting. *JHPR* 2012;1(1):1-6.
9. VandenBerg AM. Book Review Handbook of Drug Interactions: A Clinical and Forensic Guide, 2nd Edition. *Ann Pharmacother* 2012;46:906-907.
8. Phan SP, VandenBerg AM. Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics. *AJHP* 2012;69:1014-1015.
7. Freeland KN, VandenBerg A. Pharmacologic Options for the Management and Prevention of Migraines. *J Pharm Technol* 2011;27:222-8.
6. Snarr BS, Phan SV, Garner A, VandenBerg AM, Barth KS. Symptomatic Bradycardia with Oral Aripiprazole and Oral Ziprasidone. *Ann Pharmacother* 2010;44:760-3.
5. Lorenz R, VandenBerg AM, Canepa E. Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. *Int J Psych Med* 2008;38(1):81-90.
4. Wright T, VandenBerg AM. Risperidone- and quetiapine-induced cholestasis. *Ann Pharmacother* Sept 2007;41(9):1518-23.
3. Swidan S, VandenBerg AM. Headache. In: Mueller B, Bertch K, Dunsworth T, et al, eds. *Pharmacotherapy Self-Assessment Program, 4th ed. Psychiatry/Neurology Module.* Kansas City, MO: American College of Clinical Pharmacy, 2002.
2. Swidan S, Townsend KA, VandenBerg AM, Yarrows SA. Management of Hypertension in Hospitalized Elderly Patients. *American Journal of Hypertension* April 2000; 13(4 Part 2):279A.
1. *Nursing Herbal Drug Handbook.* Springhouse, PA: Springhouse Corp., 2001. Monographs for mayapple, marigold, meadowsweet, marshmallow, marjoram.

Posters

42. Dean M, Capitanov M, VandenBerg A. Lithium dosing in post-transplant patient with unstable fluid-electrolyte status. AAPP Annual Meeting April 18, 2023
41. Capitanov M, VandenBerg A. Clinical conundrums of clozapine on consult liaison psychiatry. AAPP Annual Meeting April 18, 2023
40. Brelje A, Fay B, Mariouw S, VandenBerg A. Identifying olanzapine induced liver injury in the setting of acute hepatitis C. Michigan Psychiatric Society Spring Meeting; April 14, 2022
39. Christensen H, VandenBerg A. Home antidepressant prescribing during non-psychiatric hospitalization. CPNP Annual meeting, April 24, 2022.
38. Ernst K, VandenBerg A, Thompson A. Relative exposure to psychiatric disease states and medications in pharmacy education. APhA Oct 27, 2021

37. Walkerly A, VandenBerg A. Free and total serum valproic acid concentrations: association with clinical response and toxicities. CPNP 2021 Virtual Annual Meeting (associated platform presentation and resident research award)
36. Cusimano J, VandenBerg A. Impact of medications on electroconvulsive therapy outcomes. CPNP 2020 Virtual Annual Meeting.
35. Cusimano J, Martin C, VandenBerg A. Olanzapine-induced Edema Decreasing Lithium Concentrations. CPNP 2019 Annual Meeting. Salt Lake City, UT
34. O'Connell M, Hunt E, VandenBerg A, Vertigoheel Induced Psychosis: A Case Report. CPNP 2019 Annual Meeting. Salt Lake City, UT
33. O'Connell M, VandenBerg A. Impact of pharmacist driven medication reconciliation in psychiatric emergency services on patient outcomes. CPNP 2019 Annual Meeting. Salt Lake City, UT
32. Goldsborough S, Bixby A, Iuppa A, LeBlanc A, Schultz H, VandenBerg A. Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms. CPNP 2018 Annual Meeting, Phoenix, AZ.
31. Goldsborough S, Erley J, VandenBerg A, Audu A. Loxapine in patient with clozapine-resistant psychosis. CPNP 2018 Annual Meeting, Phoenix, AZ.
28. Brueckner E, Robert S, Linder L, Ruhe AM, VandenBerg A. Creative pharmacokinetics utilized for improved efficacy in the treatment of pseudobulbar affect: combining SSRIs with dextromethorphan. South Carolina Psychiatric Association Annual Meeting Charleston, SC January 27, 2017.
27. VandenBerg A, Hallman I, Hilderbrand K, Kinsman J, Hirshbein L. Management of anxiety and agitation using electronic medical record to optimize care and interdisciplinary communication. CPNP Annual Meeting Phoenix, AZ April 2017
26. VandenBerg A. Loxapine in patient with possible clozapine-induced myocarditis. CPNP Annual Meeting Phoenix, AZ April 2017
25. McGrane I, VandenBerg A, Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis: a case report. CPNP Annual Meeting Phoenix, AZ April 2017
24. Bacon O, VandenBerg A, May M. Provider and patient perception of patient health literacy. CPNP Annual Meeting Colorado Springs, CO April 2016
23. Bacon O, Robert S, VandenBerg A. Evaluating nursing satisfaction and utilization of the clinical institute withdrawal assessment for alcohol, revised version (CIWA-Ar). CPNP Annual Meeting Tampa, FL April 2015.
22. May M, VandenBerg A. Assessment of factors leading to 30-day psychiatric readmissions. CPNP Annual Meeting Tampa, FL April 2015.
21. Crawford RE, VandenBerg A, Borckhardt J. Continuation of Asenapine, Iloperidone, and Lurasidone Versus Haloperidol and Risperidone During Inpatient Psychiatric Hospitalizations: a Retrospective Chart Review. CPNP Annual Meeting Phoenix, AZ April 2014
20. Colvard MJ, et al. Evaluation of Consumer and Provider Satisfaction with National Alliance on Mental Illness Written Medicine Information: A multi-site, collaborative pharmacy resident project. CPNP Annual Meeting Colorado Springs, CO April 2013
19. Jackson MT, et al. Collaborating Across the Country: Lessons Learned from a Multi-site, Pharmacy Resident Research Project. CPNP Annual Meeting Colorado Springs, CO April 2013
18. Ross CA, Cogdill B, VandenBerg A. Implementation and Assessment of a Psychiatric Pharmacist in the Behavioral Medicine Clinic. CPNP Annual Meeting Tampa, FL April 2012
17. Ross CA, VandenBerg A. Neuroleptic Malignant Syndrome with Concomitant Lamotrigine-Induced Rash: A Case Report. CPNP Annual Meeting Tampa, FL April 2012.
16. Freeland KN, VandenBerg A. Incidence and Course of Neuroleptic Malignant Syndrome in Patients Treated with Atypical Antipsychotics. CPNP Annual Meeting Phoenix, AZ April, 2011.
15. Ross CA, VandenBerg A. Impact of Pre-Treatment with Amobarbital on ECT Outcomes. CPNP Annual Meeting, Phoenix, AZ April, 2011.
14. Freeland KN, Ross CA, Cogdill B, Drayton SJ, Short BA, VandenBerg AM. Adherence to Evidence Based Treatment for Bipolar Depression – A Retrospective Review. ASHP Midyear Meeting Anaheim, CA December 2010.
13. Phan SV, VandenBerg A. Cost Impact of a Pharmacist-Managed Long-Acting Injectable Antipsychotic Clinic. CPNP Annual Meeting, San Antonio, TX, April 19, 2010.

12. Kreys TJ, VandenBerg A, Drayton S. Outpatient Compliance Rates with Long-Acting Injectable Antipsychotic Therapy. CPNP Annual Meeting, San Antonio, TX, April 19, 2010.
11. Miller D, Garcia D, Kreys TJ, Phan S, VandenBerg A, Garrison K. Evaluation of Accuracy of Medication Reconciliation Obtained Upon Hospital Admission at an Academic Medical Center. ASPH Midyear Clinical Meeting, Las Vegas NV, December 5, 2010.
10. Lemacks L, VandenBerg A. Automatic Therapeutic Substitution (ATS) of Risperidone and Paliperidone in Both Adult and Pediatric Patients. CPNP Annual Meeting, Scottsdale, AZ, April 13, 2008
9. Lorenz R, VandenBerg A. Medication Reconciliation in a Psychiatric Hospital. CPNP Annual Meeting, Scottsdale, AZ, April 14, 2008.
8. Lorenz R, Thompson A, Maughan M, Guirguis A, VandenBerg A. Atypical Antipsychotic Polypharmacy: Documentation of Rationale. ASHP Midyear UHC Poster Presentation, Anaheim, CA, December 2006
7. Lorenz R, VandenBerg AM. Assessment of Vital Signs in Children and Adolescents Taking ADHD Medication. CPNP Annual Meeting, Baltimore, MD, April 2006
6. Slunaker DL, VandenBerg AM, Drayton SJ. Evaluation of the Timeline to Maintenance Antipsychotic Therapy in an Inpatient Psychiatric Hospital. CPNP Annual Meeting, Baltimore, MD, April 2006
5. Mikeworth, MM, VandenBerg, AM, Hazy, J. Development and Implementation of Computerized Staff Training Modules to Teach Psychopharmacology (poster) College of Psychiatric and Neurologic Pharmacists Annual Meeting, San Diego, CA, March 2005.
4. Garris, S., VandenBerg, AM, MacFall, H. Evaluation of Ziprasidone Mesylate Guidelines for Use at the Medical University of South Carolina (MUSC) (poster) College of Psychiatric and Neurologic Pharmacists Annual Meeting, San Diego, CA, March 2005
3. Bullington, W., VandenBerg, AM, Wagner, M., McHugh, K. Development of Dose-based Guidelines of Psychotropics in Children (poster) American College of Clinical Pharmacy, Myrtle Beach, SC, April 2005
2. VandenBerg AM, Jackson CW. "Assessment of Falls in Non-Geriatric Psychiatry Inpatients." ACCP Spring Research Forum, 2002, April 16, Savannah, GA.
1. Swidan S, Townsend KA, VandenBerg AM, Yarows SA. Management of Hypertension in Hospitalized Elderly Patients. American Society of Hypertension Scientific Meeting 2000, May 20, New York, NY.

Editorial Activities

2020-present DiPiro J, ed. by. Pharmacotherapy: A Pathophysiologic Approach. Editions e11, e12, 12, and 1. Assistant Editor for Psychiatry, Neurology and Gynecologic and Obstetric Disorders

Professional Affiliations

2022-present American Society of Addiction Medicine Benzodiazepine Withdrawal Guideline Committee

2021 – present Southeastern Michigan Society of Health-System Pharmacists member

1999 - present College of Psychiatric and Neurologic Pharmacists (American Academy of Psychiatric Pharmacists as of 2022)

2015-present CPNP Mental Health Clinician Senior Editor

- Successfully collaborated to transition journal from internal, editor reviewed journal to peer-reviewed journal indexed in PubMed
- Review and make final publication decision on 40-50 manuscripts annually

2013-2015 CPNP Mental Health Clinician Editorial Board

2008-2009 CPNP Annual Meeting Programming Committee

2007-2013 CPNP/NAMI – Medication Fact Sheet Co-Editor

2006-2013 National Alliance on Mental Illness Relationship Management Group

2004-2006 Membership Committee – Mentoring Taskforce

1998 - present
2015-2017 American Society of Health-System Pharmacists
PGY2 Psychiatric Pharmacy Residency Standards Workgroup

Certifications

2002-present Board Certification in Psychiatric Pharmacy
2002, 2009 Targeted Aggression Control Training
July 1999 - present BLS Certification

Expert Opinions

The State of South Carolina vs. D.E. Broughton III February 17, 2010
Court of General Sessions; for plaintiff; retained by Office of the Solicitor 9th Judicial Circuit Court,
Charleston, Burns Wetmore.

Consulting

2019-present Wolters-Kluwer, Lexicomp Clinical Consultant Panel/content expert
2001-2006 Brand Institute, Inc Nomenclature Advisory Board Reviewer

Volunteer Activities

August 2004 – 2012 Harvest Free Medical Clinic –Volunteer Pharmacy Services
Coordinator